Point72 Asset Management 增持了市值为 23.4 亿美元的生物技术公司 Apogee Therapeutics 的股份。 Point72 Asset Management boosted its stake in Apogee Therapeutics, a biotech firm with a market cap of $2.34 billion.

资产管理公司大幅增加了其在Apogee Therapeutics的股份, Apogee Therapeutics是一家开发治疗诸如亚托皮性皮肤炎和COPD等疾病的生物技术公司. Point72 Asset Management significantly increased its stake in Apogee Therapeutics, a biotechnology company developing treatments for conditions like atopic dermatitis and COPD. 股票得到积极的分析家评级,目标价格高达110美元,机构投资者现在拥有公司79.04%的股份。 The stock has received positive analyst ratings, with target prices ranging up to $110, and institutional investors now own 79.04% of the company's shares. 公司股票于星期四52.02美元开放,协商一致的目标价格为83.88美元,市场上限为23.4亿美元。 The company's shares opened at $52.02 on Thursday, with a consensus target price of $83.88 and a market cap of $2.34 billion.